{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:49:54Z","timestamp":1790819394977,"version":"4.1.0"},"reference-count":90,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2016,8,30]]},"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of &lt;7%. Due to growing incidence, late diagnosis and insufficient treatment options, PDAC is predicted to soon become one of the leading causes of cancer-related death. Although intensified cytostatic combinations, particularly gemcitabine plus nab-paclitaxel and the folinic acid, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX) protocol, provide some improvement in efficacy and survival compared with gemcitabine alone, a breakthrough in the treatment of metastatic pancreatic cancer remains out of sight. Nevertheless, recent translational research activities propose that either modulation of the immune response or pharmacological targeting of epigenetic modifications alone, or in combination with chemotherapy, might open highly powerful therapeutic avenues in GI cancer entities, including pancreatic cancer. Deregulation of key epigenetic factors and chromatin-modifying proteins, particularly those responsible for the addition, removal or recognition of post-translational histone modifications, are frequently found in human pancreatic cancer and hence constitute particularly exciting treatment opportunities. This review summarises both current clinical trial activities and discovery programmes initiated throughout the biopharma landscape, and critically discusses the chances, hurdles and limitations of epigenetic-based therapy in future PDAC treatment.<\/jats:p>","DOI":"10.1136\/gutjnl-2016-312539","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T22:28:47Z","timestamp":1478212127000},"page":"168-179","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":111,"title":["Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?"],"prefix":"10.1136","volume":"66","clinical-trial-number":[{"clinical-trial-number":"nct00192842","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00094445","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00379639","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00372437","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00004861","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00372437","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00004861","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00667082","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01056601","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02349867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01110876","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00251589","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00738751","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01987362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02259114","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02369029","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00710710","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01434316","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01783171","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01897571","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02601950","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01023308","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Elisabeth","family":"Hessmann","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Johnsen","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T","family":"Siveke","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"West German Cancer Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Ellenrieder","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"2025120523565427000_66.1.168.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14169"},{"key":"2025120523565427000_66.1.168.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164368"},{"key":"2025120523565427000_66.1.168.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature16965"},{"key":"2025120523565427000_66.1.168.4","first-page":"809","article-title":"Current standards and novel treatment options for metastatic pancreatic adenocarcinoma","volume":"29","author":"Weinberg","year":"2015","journal-title":"Oncology"},{"key":"2025120523565427000_66.1.168.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2016.01.003"},{"key":"2025120523565427000_66.1.168.6","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201489574"},{"key":"2025120523565427000_66.1.168.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.027"},{"key":"2025120523565427000_66.1.168.8","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-014-0031-6"},{"key":"2025120523565427000_66.1.168.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature09784"},{"key":"2025120523565427000_66.1.168.10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MOG.0b013e32830b111d","article-title":"The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research","volume":"24","author":"Lomberk","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"2025120523565427000_66.1.168.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3398"},{"key":"2025120523565427000_66.1.168.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-011-9257-1"},{"key":"2025120523565427000_66.1.168.13","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00831"},{"key":"2025120523565427000_66.1.168.14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M409024200"},{"key":"2025120523565427000_66.1.168.15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/j.gastro.2009.10.045","article-title":"NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells","volume":"138","author":"K\u00f6enig","year":"2009","journal-title":"Gastroenterology"},{"key":"2025120523565427000_66.1.168.16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24695"},{"key":"2025120523565427000_66.1.168.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3066"},{"key":"2025120523565427000_66.1.168.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605039"},{"key":"2025120523565427000_66.1.168.19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4257"},{"key":"2025120523565427000_66.1.168.20","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2010.513802"},{"key":"2025120523565427000_66.1.168.21","first-page":"9384","article-title":"Therapeutic applications of curcumin for patients with pancreatic cancer","volume":"20","author":"Kanai","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025120523565427000_66.1.168.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0024"},{"key":"2025120523565427000_66.1.168.23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-010-1470-2","article-title":"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer","volume":"68","author":"Kanai","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025120523565427000_66.1.168.24","first-page":"679","article-title":"FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells","volume":"24","author":"Sato","year":"2004","journal-title":"Int J Oncol"},{"key":"2025120523565427000_66.1.168.25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3681"},{"key":"2025120523565427000_66.1.168.26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22558"},{"key":"2025120523565427000_66.1.168.27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210610"},{"key":"2025120523565427000_66.1.168.28","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1779"},{"key":"2025120523565427000_66.1.168.29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404396"},{"key":"2025120523565427000_66.1.168.30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.04.004"},{"key":"2025120523565427000_66.1.168.31","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3130"},{"key":"2025120523565427000_66.1.168.32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7744"},{"key":"2025120523565427000_66.1.168.33","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol Rep"},{"key":"2025120523565427000_66.1.168.34","first-page":"3129","article-title":"Histone deacetylase (HDAC) inhibitors: current evidence for therapeutic activities in pancreatic cancer","volume":"35","author":"Damaskos","year":"2015","journal-title":"Anticancer Res"},{"key":"2025120523565427000_66.1.168.35","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"2025120523565427000_66.1.168.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.02.013"},{"key":"2025120523565427000_66.1.168.37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3747\/co.v15i5.371","article-title":"Histone deacetylase inhibitors as novel anticancer therapeutics","volume":"15","author":"Walkinshaw","year":"2008","journal-title":"Curr Oncol"},{"key":"2025120523565427000_66.1.168.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5730"},{"key":"2025120523565427000_66.1.168.39","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-5"},{"key":"2025120523565427000_66.1.168.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3165"},{"key":"2025120523565427000_66.1.168.41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.6165"},{"key":"2025120523565427000_66.1.168.42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl081"},{"key":"2025120523565427000_66.1.168.43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2961"},{"key":"2025120523565427000_66.1.168.44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3892\/ijo.2013.2042","article-title":"A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma","volume":"43","author":"Yamada","year":"2013","journal-title":"Int J Oncol"},{"key":"2025120523565427000_66.1.168.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.02.008"},{"key":"2025120523565427000_66.1.168.46","first-page":"20","article-title":"Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma","volume":"4","author":"Weiss","year":"2013","journal-title":"J Gastrointest Oncol"},{"key":"2025120523565427000_66.1.168.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.009"},{"key":"2025120523565427000_66.1.168.48","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-015-0372-y"},{"key":"2025120523565427000_66.1.168.49","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4216-2"},{"key":"2025120523565427000_66.1.168.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.03.016"},{"key":"2025120523565427000_66.1.168.51","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3256"},{"key":"2025120523565427000_66.1.168.52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406722111"},{"key":"2025120523565427000_66.1.168.53","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504"},{"key":"2025120523565427000_66.1.168.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.05.016"},{"key":"2025120523565427000_66.1.168.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.028"},{"key":"2025120523565427000_66.1.168.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.11.003"},{"key":"2025120523565427000_66.1.168.57","doi-asserted-by":"crossref","unstructured":"McCleland ML , Mesh K , Lorenzana E , et al . CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest 2016;126:639\u201352. doi:10.1172\/JCI83265","DOI":"10.1172\/JCI83265"},{"key":"2025120523565427000_66.1.168.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.017"},{"key":"2025120523565427000_66.1.168.59","doi-asserted-by":"publisher","DOI":"10.2217\/epi.14.91"},{"key":"2025120523565427000_66.1.168.60","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.126"},{"key":"2025120523565427000_66.1.168.61","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3952"},{"key":"2025120523565427000_66.1.168.62","doi-asserted-by":"publisher","DOI":"10.1101\/gad.256628.114"},{"key":"2025120523565427000_66.1.168.63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2068"},{"key":"2025120523565427000_66.1.168.64","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0770"},{"key":"2025120523565427000_66.1.168.65","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse","volume":"4","author":"Hingorani","year":"2004","journal-title":"Cancer Cell"},{"key":"2025120523565427000_66.1.168.66","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.216"},{"key":"2025120523565427000_66.1.168.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.091"},{"key":"2025120523565427000_66.1.168.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.10.013"},{"key":"2025120523565427000_66.1.168.69","doi-asserted-by":"crossref","first-page":"17087","DOI":"10.18632\/oncotarget.7718","article-title":"Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites","volume":"7","author":"Allaway","year":"2016","journal-title":"Oncotarget"},{"key":"2025120523565427000_66.1.168.70","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.7.16475"},{"key":"2025120523565427000_66.1.168.71","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06535"},{"key":"2025120523565427000_66.1.168.72","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-011-9262-4"},{"key":"2025120523565427000_66.1.168.73","doi-asserted-by":"publisher","DOI":"10.1038\/nature08398"},{"key":"2025120523565427000_66.1.168.74","doi-asserted-by":"crossref","unstructured":"Pasini D , Bracken AP , Jensen MR , et al . Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. 2004;23:4061\u201371. doi:10.1038\/sj.emboj.7600402","DOI":"10.1038\/sj.emboj.7600402"},{"key":"2025120523565427000_66.1.168.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.06.020"},{"key":"2025120523565427000_66.1.168.76","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0037"},{"key":"2025120523565427000_66.1.168.77","first-page":"175","article-title":"Diverse involvement of EZH2 in cancer epigenetics","volume":"7","author":"V\u00f6lkel","year":"2015","journal-title":"Am J Transl Res"},{"key":"2025120523565427000_66.1.168.78","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3968"},{"key":"2025120523565427000_66.1.168.79","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i24.7830"},{"key":"2025120523565427000_66.1.168.80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1013"},{"key":"2025120523565427000_66.1.168.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2010.03.004"},{"key":"2025120523565427000_66.1.168.82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111840"},{"key":"2025120523565427000_66.1.168.83","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201500565"},{"key":"2025120523565427000_66.1.168.84","doi-asserted-by":"publisher","DOI":"10.4161\/15384047.2014.972776"},{"key":"2025120523565427000_66.1.168.85","doi-asserted-by":"publisher","DOI":"10.1038\/nature14122"},{"key":"2025120523565427000_66.1.168.86","doi-asserted-by":"publisher","DOI":"10.1038\/nature13561"},{"key":"2025120523565427000_66.1.168.87","first-page":"2142","article-title":"A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies","volume":"8","author":"Patnaik","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2025120523565427000_66.1.168.88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-546283"},{"key":"2025120523565427000_66.1.168.89","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21132"},{"key":"2025120523565427000_66.1.168.90","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.257"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2016-312539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:57:05Z","timestamp":1765007825000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2016-312539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,7]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/gutjnl-2016-312539"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2016-312539","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,3]]}}}